Immutep Limited reports clinical and corporate developments as a clinical-stage biotechnology company developing Lymphocyte Activation Gene-3 (LAG-3) related immunotherapies for cancer and autoimmune diseases. Its updates center on eftilagimod alfa (efti), a LAG-3 immunotherapy evaluated in cancer studies, and IMP761, a LAG-3 agonist antibody for autoimmune disease.
Recurring company news covers trial results and changes across programs such as TACTI-004, INSIGHT-003 and EFTISARC-NEO, FDA orphan drug designation for efti in soft tissue sarcoma, scientific-conference abstracts, development and commercialization collaborations, quarterly activities reports, cash runway commentary and Nasdaq ADR listing compliance matters.
Summary not available.